Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Thaer KhourySong Liu

Abstract

Recent trials have shown remarkable efficacy from combined trastuzumab and chemotherapy in the adjuvant setting of breast cancer. In spite of these successes, refractory breast cancer has emerged as a clinically problematic outcome for a subset of patients managed this way. In an effort to clarify and optimize the treatment regimens for breast cancer patients who are candidates to receive trastuzumab, we sought to analyze whether a distinctive genetic signature could be characterized that would reliably predict the treatment outcome. The ability to predict who will respond and who will become refractory to this agent will allow for improved, rational clinical management of these patients and further stratify the personalized nature of this treatment regimen. In this study, 41 consecutive cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patien...Continue Reading

References

Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M B EisenD Botstein
Aug 30, 2000·Nature·C M PerouD Botstein
Jan 13, 2001·Oncogene·L M Weiner, G P Adams
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Sep 8, 2001·Journal of Mammary Gland Biology and Neoplasia·K L CarrawayC A Carraway
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Dec 26, 2001·Journal of the National Cancer Institute·Y LuM Pollak
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Yih-Lin ChungSang-Hue Yen
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Hadi YazijiAllen M Gown
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Oct 21, 2004·British Journal of Cancer·N MoniauxS K Batra
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 7, 2006·Cancer Letters·Rita Nahta, Francisco J Esteva
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeanne M du ManoirRobert S Kerbel
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
May 2, 2006·Statistical Applications in Genetics and Molecular Biology·Gordon K Smyth
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce E Hillner, Thomas J Smith
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lyndsay N HarrisEric P Winer
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melinda L TelliAlice E Guardino
Oct 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chien-Hsing LuDihua Yu
May 10, 2008·Bioinformatics·Pan DuSimon M Lin

❮ Previous
Next ❯

Citations

Apr 19, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Thaer KhouryRichard T Cheney
Jan 17, 2013·Translational Oncology·Enrique Espinosa ArranzPilar Zamora
Sep 3, 2019·Scientific Reports·Seung-Myoung SonOk-Jun Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.